(SeaPRwire) –

If you’ve been tracking the medical affairs consultancy space lately, you’ll know that leadership shuffles can make or break a firm’s long-term trajectory. Elara Voss, senior analyst at Pharma Growth Insights, has spent 12 years unpacking exactly how these moves shape the sector—and LUCENT’s latest swap stands out as a masterclass in aligning leadership with core business identity. Too many fast-growing pharma consultancies sacrifice their scientific credibility to chase scale, but here, founder Matthew Goodman is doubling down on the clinical expertise that built LUCENT, while bringing in Simon Doyle to handle the strategic scaling. I’ve seen firms blow their reputation by putting non-clinical leaders in charge of medical affairs, so this split is a deliberate choice to protect the brand’s soul while expanding.

London, June 1, 2026 — LUCENT Biopharma, the specialist medical affairs consultancy founded in 2022 by Matthew Goodman, has announced a targeted leadership shuffle with immediate impact. Simon Doyle, a veteran with tenures at STEM, NeoHealthHub, and Cencora, is stepping into the CEO role, bringing decades of experience scaling health technology and pharmaceutical support services. Goodman, who launched LUCENT and served as its founding CEO, will transition to the chief medical officer position, remaining a core part of the company’s leadership team. Since its launch, LUCENT has built a niche serving biotech and pharma clients across the US, UK and Europe, acting as the critical bridge between clinical R&D science and the real-world adoption of innovative new medications. The firm’s core offerings span five integrated domains: Clinical Development, Medical Affairs, Field Medical, Medical Affairs Innovation & Technology, and Medical Operations. It currently partners with 12 of the world’s top 20 pharmaceutical organizations, has supported more than 14 global product launches, and holds deep expertise across 13 therapeutic areas. This leadership shift is explicitly tied to LUCENT’s three-year growth strategy, with Doyle tasked with scaling the business while preserving its founding culture, and Goodman doubling down on the clinical credibility that has defined the firm’s client relationships.

This leadership shift lands at a pivotal moment for the global medical affairs consultancy space. Over the past five years, the sector has seen a flood of big-name management consultancies acquire niche med affairs firms, often sidelining clinical expertise in favor of rapid revenue growth. LUCENT’s move pushes back against that trend, proving that scaling a med affairs firm doesn’t require sacrificing the scientific credibility that clients pay for. For pharma and biotech clients, the stakes are higher than ever: as value-based care takes hold, the success of a new drug depends not just on clinical trial data, but on translating that data into actionable insights for prescribers and patients. By putting Goodman— the founder who built the firm’s clinical reputation—in the CMO role, LUCENT is ensuring that every scaling move ties back to client needs and real-world clinical challenges. This model could set a new standard for mid-sized med affairs consultancies looking to expand without losing their core differentiator: the trust of their clinical and pharma partners. As more biotechs and pharma firms prioritize targeted, medically aligned support over one-size-fits-all consulting, firms that replicate this split leadership structure are likely to capture a growing share of the market.

For more details on LUCENT’s team and services, reach out to marketing manager Claire Harvey-Jones at chj@lucentbiopharma.com or visit the company’s official website at www.lucentbiopharma.com.